Next Article in Journal
Exploring the Relationship of rs2802292 with Diabetes and NAFLD in a Southern Italian Cohort—Nutrihep Study
Previous Article in Journal
Lemairamin (Wgx-50) Attenuates DSS-Induced Intestinal Inflammation in Zebrafish
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 17
10.3390/ijms25179511
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Cyclodextrin Complexes for the Treatment of Chagas Disease: A Literature Review

by
Fabrice Taio
1,
Attilio Converti
2 and
Ádley Antonini Neves de Lima
1,*
1
Department of Pharmacy, Health Sciences Center, Federal University of Rio Grande do Norte, Natal 59012-570, Brazil
2
Department of Civil, Chemical and Environmental Engineering, Pole of Chemical Engineering, Genoa University, I-16145 Genoa, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(17), 9511; https://doi.org/10.3390/ijms25179511 (registering DOI)
Submission received: 10 July 2024 / Revised: 25 August 2024 / Accepted: 27 August 2024 / Published: 1 September 2024
(This article belongs to the Special Issue Research on Cyclodextrin: Properties and Biomedical Applications)
Browse Figures
Review Reports Versions Notes

Abstract

:
Cyclodextrins are ring-shaped sugars used as additives in medications to improve solubility, stability, and sensory characteristics. Despite being widespread, Chagas disease is neglected because of the limitations of available medications. This study aims to review the compounds used in the formation of inclusion complexes for the treatment of Chagas disease, analyzing the incorporated compounds and advancements in related studies. The databases consulted include Scielo, Scopus, ScienceDirect, PubMed, LILACS, and Embase. The keywords used were “cyclodextrin AND Chagas AND disease” and “cyclodextrin complex against Trypanosoma cruzi”. Additionally, a statistical analysis of studies on Chagas disease over the last five years was conducted, highlighting the importance of research in this area. This review focused on articles that emphasize how cyclodextrins can improve the bioavailability, therapeutic action, toxicity, and solubility of medications. Initially, 380 articles were identified with the keyword “cyclodextrin AND Chagas disease”; 356 were excluded for not being directly related to the topic, using the keyword “cyclodextrin complex against Trypanosoma cruzi”. Over the last five years, a total of 13,075 studies on Chagas disease treatment were found in our literature analysis. The studies also showed interest in molecules derived from natural products and vegetable oils. Research on cyclodextrins, particularly in the context of Chagas disease treatment, has advanced significantly, with studies highlighting the efficacy of molecules in cyclodextrin complexes and indicating promising advances in disease treatment.

1. Introduction

In 1891, Antoine Villiers made a pioneering discovery by identifying crystalline dextrins and isolating the oligosaccharides derived from starch using the enzyme cyclodextrin glycosyltransferase. This initial advance was crucial for understanding the complex processes of starch transformation. Thirty years later, Freudenberg and his team detailed the structure of cyclodextrins, providing a solid foundation for future research and development. The production of these molecules in their pure form was achieved in 1984, marking a significant milestone in the field. Since then, the study and application of cyclodextrins have expanded considerably, with numerous scientific publications and patents exploring their diverse applications. Cyclodextrins have demonstrated substantial potential in the pharmaceutical and food industries, being utilized in a wide range of products and technologies [1].
Chagas disease, caused by Trypanosoma cruzi, affects millions of people globally. The WHO aims to eradicate it as a public health concern by 2030, emphasizing the importance of early diagnosis. With 6 to 8 million infected and 75 million at risk, it is a major threat in Latin America. Migration has led to new cases in non-endemic countries. Without treatment, up to 30% of those infected may develop fatal chronic heart or digestive diseases [2]. The medications for Chagas disease, nifurtimox and benznidazole, were introduced over 50 years ago and are effective only in the early stages, with many side effects. New formulations and combinations have been tested, but none have surpassed benznidazole. Therefore, the discovery of new medications is a priority. The search for more effective and safer treatments is essential to improve disease management [3].
To address these challenges, cyclodextrins are used as encapsulants because of their ability to form reversible inclusion complexes with nonpolar molecules. The formation of these complexes is determined by the structural and physicochemical characteristics of both the compounds and the cyclodextrins. They form when the guest molecule fits into the cavity of the cyclodextrins [4,5].
Cyclodextrin-based treatment is currently limited to two nitro-heterocyclic drugs, namely, nifurtimox and benznidazole, which have been the main parasiticidal agents for almost five decades. However, it is important to highlight that the safety and efficacy profiles of these drugs are far from ideal [6,7]. Although the cure efficacy is relatively low, especially in the chronic phase of the disease, in the acute phase, the treatment achieves a cure rate of 76%, but in the chronic phase, this percentage drops to only 40%. Cyclodextrin chemotherapy faces challenges due to the specific toxicity of these compounds, the presence of sensitive or resistant strains of Trypanosoma cruzi, and the existence of cross-resistance among them [8]. Therefore, it is important to pave the way for research programs aimed at developing new drugs for Chagas disease [9].
The aim of this research is to conduct a literature review to identify the potential therapeutic activities of cyclodextrins that could be effectively used in combating Chagas disease. This review also aims to present alternative molecules reported in the literature that may contribute to and serve as guidance for the treatment of this disease, focusing on aspects such as therapeutic history, biological limitations, toxicity, and the type of cyclodextrin that may favor their encapsulation. These parameters, along with the information collected from clinical and experimental studies, are crucial for drawing conclusions about the effectiveness of incorporating these molecules into cyclodextrins. Thus, this review aims to provide a comprehensive overview of the therapeutic regimen and ongoing clinical trials, highlighting the potential use of cyclodextrins to overcome some therapeutic shortcomings.

2. Flowchart of This Study

For this systematic review, we used several databases, including Scopus, ScienceDirect, Scientific Electronic Library Online (Scielo), Latin American and Caribbean Literature in Health Sciences (LILACS), Embase, and the National Center for Biotechnology Information (PubMed). Following a comprehensive search, we proceeded to exclude articles that did not align with the central theme of this research, aiming to ensure consistency and relevance in our analysis. The results revealed that we found 23 articles in PubMed, 1 in Scielo, 1 in LILACS, 45 in Scopus, 45 in Embase, and 265 in Science Direct (Figure 1). After reviewing the abstracts of the initial 380 articles, we excluded 356 of them for not being directly related to the topic at hand. Our primary objective was to establish a solid foundation for the development of the topic, selecting articles that would allow us to understand the current state of research in this area and using similar articles as reference points for a more critical analysis. To organize the article selection process, we created a flowchart outlining the selection criteria based on relevant keywords, serving as a guide to achieving our research objectives.
Table 1. Characterization of articles regarding specific studies on the inclusion of various compounds in cyclodextrins for the treatment of Chagas disease.
Table 1. Characterization of articles regarding specific studies on the inclusion of various compounds in cyclodextrins for the treatment of Chagas disease.
YearReferenceTitleGoalsConclusions
2023[10]New drug encapsulated incyclodextrin with promising anti-Trypanosoma cruzi activity.Production and Characterization of a host–guest complex (Anti-Chagas Drug-Modified Chalcone (CHC) in 2-Hydroxypropyl-Beta-Cyclodextrin).HPβCD/CHC showed promising activity against Trypanosoma cruzi. This complex offers improved water solubility and requires a lower amount of CHC to be effective.
2023[11]Elucidating the complexation of nifurtimox (NIF) with cyclodextrins.Evaluate whether the formation of complexes with β-cyclodextrin and sulfobutyl ether-β-cyclodextrin would improve the solubility and dissolution rate of the drug.β-CD/NIF and SBE-β-CD/NIF improved drug solubility and dissolution rate, showing significant stability in dissolution and crystallinity over 6 months at 25 °C and 40 °C.
2023[12]O-allyl-lawsone inclusion complex with 2-hydroxypropyl-β-cyclodextrin: Preparation, physical characterization, antiparasitic and antifunga activity.Evaluate the antiparasitic and antifungal activity of O-allyl-lawsone (OAL) free and encapsulated in 2-hydroxypropyl-β-cyclodextrin (OAL MKN) against Trypanosoma cruzi.HPβCD/OAL increased antiparasitic activity compared with the free form (OAL) while reducing cytotoxicity and enhancing selectivity for the trypomastigote form of T. cruzi.
2021[13]Characterization and trypanocidal activity of a drug carrier containing β-lapachone.Investigate the in vitro action of anti-T. cruzi, effects of β-Lap encapsulated in 2-hydroxypropyl-β-cyclodextrin (2HP-β-CD), and its potential toxicity to mammalian cells.The trypanocidal activity was increased by encapsulation of HP-β-CD/β-Lap compared with free naphthoquinone (β-Lap).
2020[14]Synthesis and biological evaluation of β-lapachone and nor-β-lapachone complexes with 2-hydroxypropyl-β-cyclodextrin as trypanocidal agents.Study βLAP and its derivative complexes nor-β-Lapachone (NβL) with 2-hydroxypropyl-β-cyclodextrin to increase solubility and bioavailability.HP-β-CD/βLAP and HP-β-CD/NβL increased the drug solubility and, additionally, vectorization was observed, resulting in higher biological activity against the epimastigote and trypomastigote forms of T. cruzi.
2022[15]Synthesis and study of the trypanocidal activity of catechol-containing 3-arylcoumarins, inclusion in β-cyclodextrin complexes and combination with benznidazole.Evaluate trypanocidal activity and cytotoxicity of a series of catechol-containing 3-arylcoumarins, their combination with BZN, and inclusion in β-cyclodextrins (β-CDs).Catechol-containing 3-arylcoumarins showed moderate trypanocidal activity against Trypanosoma cruzi, and their inclusion in β-cyclodextrins improved solubility. Combining these coumarins with benznidazole (BZN) further enhanced their effectiveness.
2018[16]Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.Conduct a literature review to identify current pharmaceutical technologies used in conjunction with BNZ to improve therapy for Chagas disease.Uma menor concentração de BNZ foi necessária para eliminar 50% das formas tripomastigotas de T. cruzi. Isso foi alcançado através da formação de complexos BNZ/CD e da modulação e vetorização do tratamento anti-Chagas utilizando estruturas metal-orgânicas.
2017[17]Benznidazole nanoformulates: A chance to improve therapeutics for Chagas disease.Describe the characterization of several encapsulated formulations of benznidazole, currently a first-line medication for the treatment of Chagas disease.The in vitro cytotoxicity of BZN/CDs was significantly lower than that of free benznidazole, while their trypanocidal activity was not impaired.
2011[18]Activity of a metronidazole analogue and its β-cyclodextrin complex against Trypanosoma cruzi.Prepare an inclusion complex between a metronidazole iodide analog (MTZ-I) and cyclodextrin (CD) to develop a safer and more effective method of treating Trypanosoma cruzi infections.MTZ-I and MTZ-I/β-CD were 10 times more active than MTZ, indicating that the presence of an iodine atom in the side chain increased trypanocidal activity while maintaining its cytotoxicity.
2011[19]Modulated dissolution rate of the antichagasic benznidazole inclusion complex and cyclodextrin using hydrophilic polymer.Investigate the utility of hydroxypropylmethylcellulose (HPMC) polymer in controlling the release of BNZ from solid inclusion complexes with cyclodextrin to overcome the problem of its bioavailability.The addition of HPMC to BZN/CD inclusion complexes significantly improved the dissolution rate and controlled drug release, showing promising potential for Chagas disease therapy.
2012[20]Benznidazole drug delivery by binary and multicomponent inclusion complexes using cyclodextrins and polymers.Develop and characterize inclusion complexes in binary systems with BNZ and randomly methylated β-cyclodextrin (RMβCD), and in ternary systems with BNZ, RMβCD, and hydrophilic polymers.Cyclodextrin-based inclusion complexes with benznidazole (BNZ) and hydrophilic polymers demonstrated effective, standardized, and safe drug delivery.
2008[21]Study of the interaction between hydroxymethyl nitrofurazone and 2-hydroxypropyl-β-cyclodextrin.Characterize an NFOH inclusion complex in 2-hydroxypropyl-β-cyclodextrin (HP-β-CD).HP-β-CD/NFOH significantly reduced the toxic effects of NFOH, according to preliminary toxicity studies and cell viability tests.
2007[22]Hydroxymethylnitrofurazone inclusion complex: dimethyl-β-cyclodextrin: a physicochemical characterization.Characterize inclusion complexes formed between NFOH and dimethyl-β-cyclodextrin (DM-β-CD) through complexation/release kinetics and solubility isotherm experiments using ultraviolet (UV)–visible spectrophotometry and dynamics measurement.NFOH/DM-β-CD showed improved solubility and favorable complexation, as demonstrated by solubility isotherm studies.

3. Brief Review

In this section, various elements related to cyclodextrin, the history of Chagas disease, and studies for its treatment are thoroughly explored.

3.1. Cyclodextrin

Natural cyclodextrins, specifically α-CDs, β-CDs, and γ-CDs, consist of sets of six, seven, and eight glucose units, respectively (Figure 2). These units are expressed differently, allowing for precise adjustment of both the potency and duration of medication action [18]. As for their synthetic counterparts, they can be categorized into three distinct classes as follows: hydrophilic, represented by 2-hydroxypropyl-β-CD (HP-β-CD); hydrophobic, exemplified by 2,6-di-O-ethyl-β-CD; and ionizable, with sulfobutyl ether β-CD (SBE-β-CD) serving as a prominent example. Cyclodextrin complexes are extensively utilized in pharmaceutical products, drug delivery systems, cosmetics, and various industries and are frequently incorporated into diverse pharmaceutical formulations [20]. Furthermore, they possess notable pharmacological properties, facilitating drug solubility, improving bioavailability, contributing to physicochemical stability, engaging in inclusion complex formation, and enhancing the sensory attributes of drugs, among other roles [23].
The pharmaceutical properties of cyclodextrins are attributed to their complex three-dimensional structure, which is a result of the abundant presence of hydroxyl groups, rendering them readily soluble in water. Cyclodextrins possess external cavities with a hydrophilic layer of water and internal cavities that repel water (hydrophobic) (Figure 3). These characteristics enable them to dissolve in aqueous solutions and encapsulate hydrophobic moieties within their cavities. The incorporation of “guest” molecules into cyclodextrin inclusion complexes in aqueous media serves as the basis for most applications in the pharmaceutical field. If the drug molecules have adequate size and properties suitable for the formation of inclusion complexes, a balanced equilibrium exists among free cyclodextrins, free drug molecules, and the inclusion complexes that form [24] (Figure 4).
Inside the cavity, there are two rings of C-H groups and a ring of glycosidic oxygen atoms, which impart hydrophobic characteristics to its internal structure. Table 2 provides a summary of the most significant physicochemical properties of natural cyclodextrins.

3.2. Industrial Applications

The cyclodextrin system is extensively explored and studied in various areas of the literature [26]. This includes fields such as food science, technology, and engineering [27,28,29], pharmaceutical industries [30,31,32,33], chemistry or chemical engineering [34,35], environmental sciences [36,37], and the cosmetics industry [38,39].

3.3. Complexation Mechanism

Cyclodextrins have the ability to form inclusion complexes in both liquid and solid media. After this complexation, they can enhance the physicochemical properties of the host substance. Cyclodextrins have the capacity to reduce the volatility of compounds, transform liquids into solids, mask the unpleasant odor and taste of certain compounds, prevent undesirable incompatibilities, improve bioavailability, and reinforce stability, even in the presence of light, heat, and oxidizing conditions. To achieve the formation of inclusion complexes with cyclodextrin, various methods are utilized, as each target substance to be encapsulated has its own particularities. The preparation of these complexes is a relatively simple process. The most common procedure involves agitating or mixing cyclodextrin in an aqueous solution that may vary in temperature (cold or hot) and pH (neutral, alkaline, or acidic), containing the molecules of the guest compound. Inclusion complexes can be acquired through a variety of techniques, including co-precipitation [40,41], co-evaporation [42,43,44,45], lyophilization and physical mixing [46], spray drying and kneading [47], and the use of supercritical fluid technology [48]. In the complexes (Figure 4), the host molecule, i.e., cyclodextrin, partially or entirely houses the guest molecule in its cavity. The formation of this complex is determined by the dimensional characteristics of both the cyclodextrin cavity and the guest molecule.

3.4. Chagas Disease

The complication of Chagas disease has been exacerbated because of recent population migrations in the Latin American continent [49]. These migrations involve the movement of people from rural to urban areas in Europe, North America [50], Japan, and Australia. Remarkably, the number of immigrants from North America to Europe doubled, from 910,402 in 2001 to over 2 million in 2004. Additionally, Japan, Australia, and Canada have experienced a significant influx of immigrants from Latin America in recent years [51]. Europe’s involvement is noteworthy, with the majority of Chagas disease cases being registered in countries such as Spain and Italy, followed by the United Kingdom, Portugal, Switzerland, France, and Sweden [52,53].
In 1909, the Brazilian doctor and scientist Carlos Ribeiro Justiniano das Chagas, as a researcher, managed to clarify and elucidate the contamination from the main vector to the host, the infecting forms, and the biological cycle. Chagas disease is caused by the flagellated protozoan Trypanosoma cruzi, which is an etiological agent. This parasite has an extensive biological cycle and goes through several evolutionary forms within the vertebrate host (man) and in insect vectors including triatomines, which are a family of insects in the order Hemiptera, suborder Heteroptera, family Reduviidae, popularly known as “kissing bugs” [54].

3.5. Biological Cycle

As shown in Figure 5, the biological cycle of T. cruzi begins with the penetration of the trypomastigote forms present in triatomine feces into the intact mucosa or damaged skin of the host after the insect has taken a blood meal. Then, the metacyclic trypomastigote forms penetrate the cells and differentiate into amastigotes. This form multiplies by binary division within the cell and differentiates again into trypomastigotes, which, through the rupture of the parasitized cell, are released into the circulating blood and can again infect another cell or be ingested by the insect. When the triatomine takes a blood meal in hosts infected by T. cruzi, it ingests the trypomastigote form, which in the insect’s midgut differentiates into the epimastigote form of the parasite and multiplies. Then, in the rectal ampulla of the vector, these forms differentiate again into trypomastigotes, which are again capable of infecting new hosts [55,56].

3.6. Nifurtimox and Benznidazole

In the 1970s, the following compounds were identified for the treatment of CD: nifurtimox and benznidazole [57], whose structures are depicted in Figure 6. These medications are used with the purpose of reducing both the duration and severity of the symptoms of the disease. The main benefits expected from treatment include reducing the presence of parasites in the body (parasitemia), preventing disease reactivation, increasing the patient’s life expectancy, and reducing clinical complications [9]. The first-line treatment is benznidazole, often chosen because of its safety and efficacy profile [58].
Nifurtimox works by generating oxygen, which leads to the intoxication of the parasite. Consequently, it can cause damage to the host’s tissues, thereby explaining the manifestation of several side effects. On the other hand, benznidazole does not cause oxidative damage in its antiparasitic action; instead, it blocks the production of proteins and RNA in both extracellular and intracellular forms found in the parasitized host [59]. Since the 1980s, the sale of nifurtimox has been suspended, initially in Brazil and later in other South American nations. The main drawback associated with both medications is their unwanted side effects (see Table 3) [59].

3.7. Studies Conducted on the Treatment of T. cruzi

After the acute phase, survivors enter the chronic phase of Chagas disease, often characterized by the absence of visible symptoms, which can persist indefinitely. Over time, patients in this phase may develop symptoms related to the cardiovascular, digestive, or both systems, resulting in cardiac and digestive forms of the disease [61]. Because of the disease’s prevalence in low-income populations, there has been little interest from the pharmaceutical industry in investing in treatments, as they do not represent significant financial returns. The complexity of the disease and limited resources allocated to research in this area has contributed to the scarcity of therapeutic advances over the decades. To date, no new drugs have been developed for the treatment of Chagas disease, as reported by the U.S. Food and Drug Administration. However, academic interest in the topic is significant, especially in public higher education institutions in Latin America [62]. To advance in this scenario, recent research has focused on the treatment of Chagas disease. Over the past five years, our analysis of the scientific literature revealed a total of 2655 studies in PubMed, 19 in Scielo, 144 in LILACS, 3106 in Embase, 5345 in ScienceDirect, and 1806 in Scopus (Figure 7).

4. Impact of Cyclodextrins on the Optimization of Drug Solubility and Efficacy

Despite the theoretical and practical importance of cyclodextrins and the extensive literature on them, their significant potential is still not well understood, requiring further research on their structure and properties. A promising area is the modification of standard cyclodextrins to enhance their complexation capacity with various substances, whether by inclusion in the cavity or binding to the external surface. Additionally, it is essential to investigate the physicochemical properties of the aqueous solutions of these systems to better understand the interactions between host and guest, as well as the inclusion complex with the aqueous solvent [63].
Cyclodextrins are chemically versatile and can be modified to produce mono- or polysubstituted derivatives, which can enhance their properties, such as solubility and stability, and adjust their complexation abilities. The process of complexation leads to significant changes in the spectral properties, reactivity, volatility, solubility, and stability of guest compounds. Thus, cyclodextrins hold great potential for application in various technological fields [64].
The structure of the inclusion complex that is formed depends on the drug and the cyclodextrins used, which can stabilize some drugs while destabilizing others. The effectiveness of stabilization is influenced by the types of cyclodextrins employed in the complexation. Although binary complexes of cyclodextrins and drugs can improve stability, cyclodextrins with low complexation efficiency may require higher concentrations to form these complexes. Adding a ternary agent to a binary complex can increase the stability constant and efficiency because of the synergistic interaction between the components. However, a third component that competes for inclusion in the cyclodextrin cavity can reduce overall efficiency, making the appropriate selection of ternary compounds crucial for the development of supramolecular systems. To achieve the desired drug stability, it is essential to identify which cyclodextrins provide the greatest stabilizing effect and determine the most suitable concentrations for each case [65].

5. Impact of Cyclodextrins with Benznidazole in the Treatment of Chagas Disease

Researchers are exploring new approaches for treating Chagas disease. Years of research have evolved with fresh perspectives on finding the best drug for T. cruzi. Thus, the research has focused on established drugs against Chagas disease, such as benznidazole. Soares-Sobrinho et al. [20] developed and characterized inclusion complexes with benznidazole and randomly methylated β-cyclodextrin (RMβCD), demonstrating that methylated cyclodextrins are a reliable and safe option for effective drug delivery. In the same year, Vinuesa et al. [17] developed nanoformulations of benznidazole in cyclodextrin, which reduced toxicity without compromising efficacy against Trypanosoma cruzi, indicating a potential improvement in Chagas disease treatment. Additionally, Ferraz et al. [16] highlighted the efficacy of benznidazole at low concentrations, while Sá-Barreto et al. [19] proposed BNZ-HPβCD to enhance drug bioavailability. Finally, Pozo-Martínez et al. [15] observed that flavonoids combined with benznidazole in complexes with β-cyclodextrins increased drug solubility. These findings represent promising advances in the search for more effective and safer treatments for Chagas disease.
These discoveries signify promising strides towards more effective and safer treatments for Chagas disease. The evolution of studies with benznidazole has demonstrated significant progress over the years, with the development of inclusion complexes and nanoformulations that enhance efficacy and reduce toxicity. Cyclodextrins, especially β-cyclodextrins and their derivatives, have proven to be valuable tools in improving the solubility and bioavailability of benznidazole, offering new opportunities for more effective and safer treatments against Trypanosoma cruzi.

6. Impact of Cyclodextrins with Natural Products in the Treatment of Chagas Disease

Research in the field of Chagas disease treatment has advanced significantly, overcoming the limitations of existing medications and exploring new approaches. There is a growing emphasis on the use of β-cyclodextrins and their derivatives (Table 4), as well as natural molecules (Table 5), to develop more effective formulations. Comparative studies have shown that metronidazole iodide is 10 times more potent against Trypanosoma cruzi, maintaining cytotoxicity when complexed with β-cyclodextrin [19]. In 2023, Bedogni et al. [11] investigated the complexation of nifurtimox with cyclodextrins to enhance the drug’s solubility and dissolution, achieving a stable complex. Nicoletti et al. [12] found increased antiparasitic and antifungal activity of O-allyl-lawsone (OAL) when complexed with β-cyclodextrin. Zanetti et al. [10] highlighted the antiparasitic activity of chalcone complexes with hydroxypropyl β-cyclodextrin, along with improved water solubility. Over the years, cyclodextrins have emerged as crucial tools for overcoming the limitations faced by various compounds [66]. Nitrofurazone, initially active against Gram-positive microorganisms, later demonstrated efficacy against Trypanosoma cruzi [67]. Studies involving cyclodextrin inclusion complexes, such as DM-β-CD and HP-β-CD, have shown increased solubility and reduced toxicity [21,22]. β-lapachone, derived from natural products and chemically known as 3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione, belonging to the Bignoniaceae family and commonly found in Brazil [68], has also been studied in relation to Trypanosoma cruzi [69]. Complexes formed with 2-hydroxypropyl-β-cyclodextrin increased the drug’s solubility, resulting in enhanced trypanocidal activity [13,14]. Cyclodextrin complexes with various drugs have demonstrated significant improvements in solubility, stability, and antiparasitic activity against Trypanosoma cruzi (T. cruzi), often resulting in reduced cytotoxicity and safer treatments. The combination of benznidazole (BZN) with cyclodextrins and hydrophilic polymers has enhanced both the efficacy and safety of treatments, presenting a promising approach for Chagas disease and other parasitic infections. Cyclodextrins such as HP-β-CD and SBE-β-CD have proven particularly effective in improving drug bioavailability and enhancing antiparasitic activities by forming stable complexes and reducing toxicity. The data in Table 1, Table 4 and Table 5 indicate that β-cyclodextrin derivatives are crucial in this context as they increase drug solubility and enhance therapeutic efficacy. Additionally, the incorporation of polymers and other agents can further amplify therapeutic effects and minimize side effects. The significance of cyclodextrins in developing new treatments for Chagas disease is evident, as they optimize pharmacological properties and reduce drug toxicity. These advances highlight the ongoing relevance of research into cyclodextrins and natural products, promoting innovations that have the potential to transform therapeutic strategies for Chagas disease.

7. Discussion

Nowadays, the use of natural products in complexation with cyclodextrins represents a promising and relevant strategy in pharmaceutical research. Research involving cyclodextrins with natural products aims not only to enhance the efficacy of bioactive molecules but also to explore their therapeutic properties in a safer and more effective manner [80]. The example of thymol, a natural compound with various beneficial properties such as antioxidant, antiseptic, and antifungal [81], illustrates how complexation with cyclodextrins like γ-cyclodextrin can enhance its applications, as demonstrated in studies by Zhang Y. and colleagues [82]. Additionally, the application of HP-β-cyclodextrin by Serna-Escolano et al. [83] as an alternative to synthetic fungicides highlights the potential of cyclodextrins in food preservation and protection against diseases.
Naphthoquinones are abundant natural products derived from naphthalene that constitute the quinone group fused to a benzene ring [84] and exhibit activity against fungi [68] and Chagas disease [85]. Studies on naphthoquinones, such as the one conducted by Oliveira da Silva and colleagues [86], underscore the growing importance of exploring natural compounds for treatments against diseases such as Chagas disease and viral infections like SARS-CoV-2. The complexation ability of β-cyclodextrin and its methylated derivatives proves crucial not only for improving the solubility and bioavailability of these compounds but also for enhancing their pharmacological properties.
Thus, the use of natural products in combination with cyclodextrins not only expands therapeutic possibilities but also represents a significant step towards more effective and safer treatments, contributing to ongoing advancements in research and therapeutic innovation.
Many studies indicate that the inclusion of cyclodextrins is widely used in the complexation of plant-derived molecules, especially terpenes, resinous oils, and essential oils, aiming to enhance their chemical and pharmacological properties [10,87]. Encapsulated vegetable oils in carriers have shown effectiveness in improving physical stability under light and heat conditions, increasing bioavailability, and reducing unpleasant aromas and flavors, as well as decreasing volatility and toxicity. Thus, molecular complexation with cyclodextrin emerges as a promising technique for encapsulating these oils [88,89].
Copaiba oil, extracted from the tree of the same name common in the Amazon region of Brazil [90], is recognized for its antimicrobial, healing, analgesic, antitumor, anti-inflammatory, and Trypanosoma cruzi properties [91,92,93,94,95,96]. Biologically, caryophyllenes are responsible for the recognized therapeutic properties of copaiba oil [97]. Components present in copaiba oils face challenges such as degradation, oxidation, storage, unpleasant taste and odor, and low water miscibility. To address these challenges effectively, oil complexation with cyclodextrins emerges as a practical solution. In addition to overcoming these limitations, complexation can offer a way to produce solid materials from the complexation, potentially yielding derivatives with improved solubility, stability, and better taste [95]. However, toxicity varies according to the route of administration, with the use of parenteral and intravenous routes discouraged because of the risk of nephrotoxicity [98,99].
This focus on the use of vegetable oils complexed with cyclodextrins not only demonstrates promising advances in research but also highlights the potential of these formulations as innovative therapeutic alternatives for treating various diseases, such as Chagas disease.

8. Final Considerations

It is worth noting that a large number of in-depth studies have been published on complexation with cyclodextrins since the beginning, mainly focused on the two drug alternatives that existed at the time, nifurtimox and benznidazole, which revealed they were more active in the acute phase of Chagas disease [100]. Benznidazole has limited solubility and low permeability [101]. Thus, cyclodextrin was mixed with benznidazole to achieve the best results in terms of efficacy and tolerance [102]. All articles involving studies with modified, combined, or synthesized benznidazole along with cyclodextrins showed positive results in terms of bioavailability, solubility, and low toxicity [17,18,19,20]. Nevertheless, benznidazole is not recommended, nor is it the choice in the chronic phase, with practically no effect [103]. Although various efforts have been made to seek new therapeutic targets, the treatment of Chagas disease continues without an effective solution. Therefore, derivatives or drug base families (nifurtimox and benznidazole) and natural products from plants with antiprotozoal [104] and antibacterial properties are being explored along with the technique of inclusion complexation. These are potent, thanks to complexation, and have the potential for therapeutic effect in any stage of the disease [105]. Unfortunately, many studies have stopped at in vitro tests, and few have progressed to in vivo tests [104].

9. Conclusions

Research on cyclodextrins has witnessed remarkable growth in recent years, expanding into a wide range of disciplines and finding applications in various innovative technologies. This progress highlights the potential of these molecules to address complex challenges across multiple fields, including medicine. Specifically, in the context of Chagas disease treatment, cyclodextrins have emerged as a promising solution for enhancing drug bioavailability, a critical factor in increasing therapeutic efficacy. This is attributed to their favorable mechanism of action against the Trypanosoma cruzi parasite, the causative agent of the disease.
Between 2007 and 2023, a series of in-depth studies have underscored the importance of incorporating both natural and synthetic drugs into cyclodextrin complexes. These studies have shown promising results, providing evidence that complexation with cyclodextrins can significantly improve the physicochemical properties of drugs, such as solubility and stability, while also enhancing their biological activities against T. cruzi. Such findings suggest that these complexes could represent a substantial advancement in the fight against Chagas disease, particularly in critical phases of treatment where drug efficacy is limited.
Given the severity of Chagas disease and the urgent need for more effective therapies, it is crucial that research continues, with a special focus on preclinical phases. These additional studies are essential for refining our understanding of the interactions between cyclodextrins and drugs and for developing therapeutic approaches that could eventually be scaled up to combat this devastating disease. The continuation and deepening of this research could pave the way for more effective, safe, and accessible treatments, offering hope to millions of people affected by Chagas disease.

Author Contributions

Conceptualization, Á.A.N.d.L. and F.T.; methodology, F.T.; software, F.T.; validation, Á.A.N.d.L. and A.C.; formal analysis, F.T.; investigation, Á.A.N.d.L. and F.T.; resources, Á.A.N.d.L.; data curation, F.T.; writing—original draft preparation, F.T.; writing—review and editing, Á.A.N.d.L. and A.C.; visualization, Á.A.N.d.L. and A.C.; supervision, Á.A.N.d.L.; project administration, Á.A.N.d.L.; funding acquisition, Á.A.N.d.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brazil (CAPES-Finance Code 001).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Crini, G. Review: A History of Cyclodextrins. Chem. Rev. 2014, 114, 10940–10975. [Google Scholar] [CrossRef]
  2. Schijman, A.G.; Alonso-Padilla, J.; Britto, C.; Herrera Bernal, C.P. Retrospect, advances and challenges in Chagas disease diagnosis: A comprehensive review. Lancet Reg. Health Am. 2024, 36, 100821. [Google Scholar] [CrossRef] [PubMed]
  3. Pérez-Molina, J.A.; Molina, I. Chagas disease. Lancet 2018, 391, 82–94. [Google Scholar] [CrossRef] [PubMed]
  4. Goldenberg, S. Chagas disease treatment: A 120-year-old challenge to public health. Memórias Do Inst. Oswaldo Cruz 2022, 117, e210501chgsa. [Google Scholar] [CrossRef]
  5. Garibyan, A.; Terekhova, I. Complex formation with modified cyclodextrins for improving biopharmaceutical properties of baricitinib, a novel immunomodulatory drug. J. Mol. Liq. 2024, 406, 125016. [Google Scholar] [CrossRef]
  6. Paiva-Santos, A.C.; Ferreira, L.; Peixoto, D.; Silva, F.; Soares, M.J.; Zeinali, M.; Zafar, H.; Mascarenhas-Melo, F.; Raza, F.; Mazzola, P.G.; et al. Cyclodextrins as an encapsulation molecular strategy for volatile organic compounds—Pharmaceutical applications. Colloids Surf. B Biointerfaces 2022, 218, 112758. [Google Scholar] [CrossRef]
  7. Pandey, R.P.; Nascimento, M.S.; Moore, C.E.; Raj, V.S.; Kalil, J.; Cunha-Neto, E. New Approaches for the Treatment of Chagas Disease. Curr. Drug Targets 2021, 22, 835–841. [Google Scholar] [CrossRef] [PubMed]
  8. Sguassero, Y.; Cuesta, C.B.; Roberts, K.N.; Hicks, E.; Comandé, D.; Ciapponi, A.; Sosa-Estani, S. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies. PLoS ONE 2015, 10, e0139363. [Google Scholar] [CrossRef] [PubMed]
  9. Dias, L.C.; Dessoy, M.A.; Silva, J.J.N.; Thiemann, O.H.; Oliva, G.; Andricopulo, A.D. Quimioterapia da doença de Chagas: Estado da arte e perspectivas no desenvolvimento de novos fármacos. Química Nova 2009, 32, 2444–2457. [Google Scholar] [CrossRef]
  10. Zanetti, I.; do Nascimento Oliveira, L.; de Azevedo Maia, F.L.; de Santiago-Silva, K.M.; Pereira, P.M.L.; Albuquerque, M.G.; Gonçalves, R.S.B.; de Lima Ferreira Bispo, M.; Yamada-Ogatta, S.F.; Magalhães, A.; et al. Cyclodextrin-encapsulated new drug with promising anti-Trypanosoma cruzi activity. J. Therm. Anal. Calorim. 2023, 148, 10821–10834. [Google Scholar] [CrossRef]
  11. Bedogni, G.; Arrúa, E.; Seremeta, K.; Okulik, N.; Salomon, C. Elucidating the complexation of nifurtimox with cyclodextrins. J. Mol. Liq. 2023, 382, 121852. [Google Scholar] [CrossRef]
  12. Nicoletti, C.D.; dos Santos Galvão, R.M.; de Sá Haddad Queiroz, M.; Barboclher, L.; Faria, A.F.M.; Teixeira, G.P.; Souza, A.L.A.; de Carvalho da Silva, F.; Ferreira, V.F.; da Silva Lima, C.H.; et al. Inclusion complex of O-allyl-lawsone with 2-hydroxypropyl-β-cyclodextrin: Preparation, physical characterization, antiparasitic and antifungal activity. J. Bioenerg. Biomembr. 2023, 55, 233–248. [Google Scholar] [CrossRef] [PubMed]
  13. Barbosa, J.M.C.; Nicoletti, C.D.; da Silva, P.B.; Melo, T.G.; Futuro, D.O.; Ferreira, V.F.; Salomão, K. Characterization and trypanocidal activity of a β-lapachone-containing drug carrier. PLoS ONE 2021, 16, e0246811. [Google Scholar] [CrossRef] [PubMed]
  14. Nicoletti, C.D.; Faria, A.F.M.; de Sá Haddad Queiroz, M.; dos Santos Galvão, R.M.; Souza, A.L.A.; Futuro, D.O.; Faria, R.X.; Ferreira, V.F. Synthesis and biological evaluation of β-lapachone and nor-β-lapachone complexes with 2-hydroxypropyl-β-cyclodextrin as trypanocidal agents. J. Bioenerg. Biomembr. 2020, 52, 185–197. [Google Scholar] [CrossRef]
  15. Pozo-Martínez, J.; Salgado, F.; Liempi, A.; Kemmerling, U.; Mera-Adasme, R.; Olea-Azar, C.; Moncada-Basualto, M.; Borges, F.; Uriarte, E.; Matos, M.J. Synthesis and study of the trypanocidal activity of catechol-containing 3-arylcoumarins, inclusion in β-cyclodextrin complexes and combination with benznidazole. Arab. J. Chem. 2022, 15, 103641. [Google Scholar] [CrossRef]
  16. de Ferraz, L.R.M.; Alves, A.É.G.; da Nascimento, D.D.S.S.; Amariz, I.A.; Ferreira, A.S.; Costa, S.P.M.; Rolim, L.A.; Lima, Á.A.N.; Rolim Neto, P.J. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole. Acta Trop. 2018, 185, 127–132. [Google Scholar] [CrossRef]
  17. Vinuesa, T.; Herráez, R.; Oliver, L.; Elizondo, E.; Acarregui, A.; Esquisabel, A.; Pedraz, J.L.; Ventosa, N.; Veciana, J.; Viñas, M. Benznidazole Nanoformulates: A Chance to Improve Therapeutics for Chagas Disease. Am. J. Trop. Med. Hyg. 2017, 97, 1469–1476. [Google Scholar] [CrossRef]
  18. Lopes, M.S.; Sales Júnior, P.A.; Lopes, A.G.F.; Yoshida, M.I.; Silva, T.H.A.; Romanha, A.J.; Alves, R.J.; Oliveira, R.B. The activity of a metronidazole analogue and its β-cyclodextrin complex against. Trypanos. Cruzi. Memórias Do Inst. Oswaldo Cruz 2011, 106, 1055–1057. [Google Scholar] [CrossRef]
  19. Sá-Barreto, L.C.L.; Gustmann, P.C.; Garcia, F.S.; Maximiano, F.P.; Novack, K.M.; Cunha-Filho, M.S.S. Modulated dissolution rate from the inclusion complex of antichagasic benznidazole and cyclodextrin using hydrophilic polymer. Pharm. Dev. Technol. 2013, 18, 1035–1041. [Google Scholar] [CrossRef] [PubMed]
  20. Soares-Sobrinho, J.L.; Santos, F.L.A.; Lyra, M.A.M.; Alves, L.D.S.; Rolim, L.A.; Lima, A.A.N.; Nunes, L.C.C.; Soares, M.F.R.; Rolim-Neto, P.J.; Torres-Labandeira, J.J. Benznidazole drug delivery by binary and multicomponent inclusion complexes using cyclodextrins and polymers. Carbohydr. Polym. 2012, 89, 323–330. [Google Scholar] [CrossRef]
  21. Grillo, R.; Melo, N.F.S.; Moraes, C.M.; de Lima, R.; Menezes, C.M.S.; Ferreira, E.I.; Rosa, A.H.; Fraceto, L.F. Study of the interaction between hydroxymethylnitrofurazone and 2-hydroxypropyl-β-cyclodextrin. J. Pharm. Biomed. Anal. 2008, 47, 295–302. [Google Scholar] [CrossRef] [PubMed]
  22. Grillo, R.; Melo, N.F.S.; Fraceto, L.F.; Brito, C.L.; Trossini, G.H.G.; Menezes, C.M.S.; Ferreira, E.I.; Moraes, C.M. Physicochemical characterization of the inclusion complex between hydroxymethylnitrofurazone and hydroxypropyl-beta-cyclodextrin. Química Nova 2008, 31, 290–295. [Google Scholar] [CrossRef]
  23. Carneiro, S.; Costa Duarte, F.; Heimfarth, L.; Siqueira Quintans, J.; Quintans-Júnior, L.; Veiga Júnior, V.; Neves de Lima, Á. Cyclodextrin–Drug Inclusion Complexes: In Vivo and In Vitro Approaches. Int. J. Mol. Sci. 2019, 20, 642. [Google Scholar] [CrossRef]
  24. Santos, C.R. da S.; Silva, É.A. Cyclodextrins: Possible therapeutic agents in neurodegenerative diseases. Res. Soc. Dev. 2022, 11, e400111335610. [Google Scholar] [CrossRef]
  25. Davis, M.E.; Brewster, M.E. Cyclodextrin-based pharmaceutics: Past, present and future. Nat. Rev. Drug Discov. 2004, 3, 1023–1035. [Google Scholar] [CrossRef]
  26. Del Valle, E.M.M. Cyclodextrins and their uses: A review. Process Biochem. 2004, 39, 1033–1046. [Google Scholar] [CrossRef]
  27. Cid-Samamed, A.; Rakmai, J.; Mejuto, J.C.; Simal-Gandara, J.; Astray, G. Cyclodextrins inclusion complex: Preparation methods, analytical techniques and food industry applications. Food Chem. 2022, 384, 132467. [Google Scholar] [CrossRef] [PubMed]
  28. Fenyvesi, É.; Vikmon, M.; Szente, L. Cyclodextrins in Food Technology and Human Nutrition: Benefits and Limitations. Crit. Rev. Food Sci. Nutr. 2016, 56, 1981–2004. [Google Scholar] [CrossRef]
  29. Hu, Y.; Qiu, C.; Qin, Y.; Xu, X.; Fan, L.; Wang, J.; Jin, Z. Cyclodextrin–phytochemical inclusion complexes: Promising food materials with targeted nutrition and functionality. Trends Food Sci. Technol. 2021, 109, 398–412. [Google Scholar] [CrossRef]
  30. Yildiz, Z.I.; Celebioglu, A.; Kilic, M.E.; Durgun, E.; Uyar, T. Menthol/cyclodextrin inclusion complex nanofibers: Enhanced water-solubility and high-temperature stability of menthol. J. Food Eng. 2018, 224, 27–36. [Google Scholar] [CrossRef]
  31. Jansook, P.; Ogawa, N.; Loftsson, T. Cyclodextrins: Structure, physicochemical properties and pharmaceutical applications. Int. J. Pharm. 2018, 535, 272–284. [Google Scholar] [CrossRef] [PubMed]
  32. Lima, P.S.S.; Lucchese, A.M.; Araújo-Filho, H.G.; Menezes, P.P.; Araújo, A.A.S.; Quintans-Júnior, L.J.; Quintans, J.S.S. Inclusion of terpenes in cyclodextrins: Preparation, characterization and pharmacological approaches. Carbohydr. Polym. 2016, 151, 965–987. [Google Scholar] [CrossRef]
  33. Ryzhakov, A.; do Thi, T.; Stappaerts, J.; Bertoletti, L.; Kimpe, K.; Sá Couto, A.R.; Saokham, P.; van den Mooter, G.; Augustijns, P.; Somsen, G.W.; et al. Self-Assembly of Cyclodextrins and Their Complexes in Aqueous Solutions. J. Pharm. Sci. 2016, 105, 2556–2569. [Google Scholar] [CrossRef] [PubMed]
  34. Noël, S.; Léger, B.; Ponchel, A.; Sadjadi, S.; Monflier, E. Cyclodextrins as multitask agents for metal nano-heterogeneous catalysis: A review. Environ. Chem. Lett. 2021, 19, 4327–4348. [Google Scholar] [CrossRef]
  35. Tang, W.; Zou, C.; Da, C.; Cao, Y.; Peng, H. A review on the recent development of cyclodextrin-based materials used in oilfield applications. Carbohydr. Polym. 2020, 240, 116321. [Google Scholar] [CrossRef] [PubMed]
  36. Verma, M.; Lee, I.; Hong, Y.; Kumar, V.; Kim, H. Multifunctional β-Cyclodextrin-EDTA-Chitosan polymer adsorbent synthesis for simultaneous removal of heavy metals and organic dyes from wastewater. Environ. Pollut. 2022, 292, 118447. [Google Scholar] [CrossRef]
  37. Liu, Z.; Ye, L.; Xi, J.; Wang, J.; Feng, Z. Cyclodextrin polymers: Structure, synthesis, and use as drug carriers. Prog. Polym. Sci. 2021, 118, 101408. [Google Scholar] [CrossRef]
  38. Loftsson, T.; Duchene, D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm. 2007, 329, 1–11. [Google Scholar] [CrossRef]
  39. Szejtli, J. Introduction and General Overview of Cyclodextrin Chemistry. Chem. Rev. 1998, 98, 1743–1754. [Google Scholar] [CrossRef]
  40. Silva, R.M.; de Araújo, M.P.; Piauilino, C.A.; Rocha, M.S.; Silva, I.S.; da Silva, F.I.; Lima, F.C.A.; Almeida, F.R. de C.; Meneses, A.K.S.; de Sousa, S.A.A.; et al. Inclusion complex of 2-phenylethanol in β-cyclodextrin: Preparation, characterization, computational study and evaluation of antinociceptive activity. J. Mol. Struct. 2024, 1318, 139236. [Google Scholar] [CrossRef]
  41. Francis, S.M.; Xavier, E.N. Solubility Enhancement of Lawsone by Complexation with Beta Cyclodextrin. Indian J. Pharm. Educ. Res. 2022, 56, 706–715. [Google Scholar] [CrossRef]
  42. Manolikar, M.K.; Sawant, M.R. Study of solubility of isoproturon by its complexation with β-cyclodextrin. Chemosphere 2003, 51, 811–816. [Google Scholar] [CrossRef] [PubMed]
  43. Rudrangi, S.R.S.; Bhomia, R.; Trivedi, V.; Vine, G.J.; Mitchell, J.C.; Alexander, B.D.; Wicks, S.R. Influence of the preparation method on the physicochemical properties of indomethacin and methyl-β-cyclodextrin complexes. Int. J. Pharm. 2015, 479, 381–390. [Google Scholar] [CrossRef] [PubMed]
  44. Scalia, S.; Molinari, A.; Casolari, A.; Maldotti, A. Complexation of the sunscreen agent, phenylbenzimidazole sulphonic acid with cyclodextrins: Effect on stability and photo-induced free radical formation. Eur. J. Pharm. Sci. 2004, 22, 241–249. [Google Scholar] [CrossRef] [PubMed]
  45. Alghaith, A.F.; Mahrous, G.M.; Alenazi, A.S.; ALMufarrij, S.M.; Alhazzaa, M.S.; Radwan, A.A.; Alhamed, A.S.; bin Salamah, M.S.; Alshehri, S. Dissolution enhancement of Gefitinib by solid dispersion and complexation with β-cyclodextrins: In vitro testing, cytotoxic activity, and tablet formulation. Saudi Pharm. J. 2024, 32, 102070. [Google Scholar] [CrossRef]
  46. Jagdale, S.C.; Gawali, V.U.; Kuchekar, B.S.; Chabukswar, A.R. Formulation and in vitro evaluation of taste-masked oro-dispersible dosage form of diltiazem hydrochloride. Braz. J. Pharm. Sci. 2011, 47, 907–916. [Google Scholar] [CrossRef]
  47. Da Silva Pires, Y.M.; Almeida, L.R.; Araújo Meirelles, L.M. Tenoxicam dissolution profile in the beta-cyclodextrin inclusion complex. Rev. Eletrônica De Farmácia 2016, 13, 64. [Google Scholar] [CrossRef]
  48. Hassan, H.A.; Al-Marzouqi, A.H.; Jobe, B.; Hamza, A.A.; Ramadan, G.A. Enhancement of dissolution amount and in vivo bioavailability of itraconazole by complexation with β-cyclodextrin using supercritical carbon dioxide. J. Pharm. Biomed. Anal. 2007, 45, 243–250. [Google Scholar] [CrossRef]
  49. Klein, N.; Hurwitz, I.; Durvasula, R. Globalization of Chagas Disease: A Growing Concern in Nonendemic Countries. Epidemiol. Res. Int. 2012, 2012, 136793. [Google Scholar] [CrossRef]
  50. Echavarría, N.G.; Echeverría, L.E.; Stewart, M.; Gallego, C.; Saldarriaga, C. Chagas Disease: Chronic Chagas Cardiomyopathy. Curr. Probl. Cardiol. 2021, 46, 100507. [Google Scholar] [CrossRef] [PubMed]
  51. Gascon, J.; Bern, C.; Pinazo, M.-J. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 2010, 115, 22–27. [Google Scholar] [CrossRef] [PubMed]
  52. Posada, E.; Pell, C.; Angulo, N.; Pinazo, M.J.; Gimeno, F.; Elizalde, I.; Gysels, M.; Muñoz, J.; Pool, R.; Gascón, J. Bolivian migrants with Chagas disease in Barcelona, Spain: A qualitative study of dietary changes and digestive problems. Int. Health 2011, 3, 289–294. [Google Scholar] [CrossRef]
  53. Strasen, J.; Williams, T.; Ertl, G.; Zoller, T.; Stich, A.; Ritter, O. Epidemiology of Chagas disease in Europe: Many calculations, little knowledge. Clin. Res. Cardiol. 2014, 103, 1–10. [Google Scholar] [CrossRef] [PubMed]
  54. Chagas, C. New human trypanozomiasis: Studies on the morphology and evolutionary cycle of Schizotrypanum cruzi n. gen., n. sp., etiological agent of a new morbid entity in man. Memórias Do Inst. Oswaldo Cruz 1909, 1, 159–218. [Google Scholar] [CrossRef]
  55. da Pita, S.S.R.; Pascutti, P.G. Therapeutic Targets in Chagas’ Disease: A Focus on Trypanothione Reductase. Rev. Virtual De Química 2011, 3, 307–324. [Google Scholar] [CrossRef]
  56. Costa, M.; Tavares, V.; Aquino, M.V.; Moreira, D. Chagas disease: A bibliographical review. Rev. Eletrônica Da Fac. De Ceres 2013, 2, 3. [Google Scholar] [CrossRef]
  57. Scariot, D.B.; Staneviciute, A.; Zhu, J.; Li, X.; Scott, E.A.; Engman, D.M. Leishmaniasis and Chagas disease: Is there hope in nanotechnology to fight neglected tropical diseases? Front. Cell. Infect. Microbiol. 2022, 12, 1000972. [Google Scholar] [CrossRef]
  58. Rassi, A., Jr.; Rassi, A.; Marin-Neto, J.A. Chagas disease. Lancet 2010, 375, 1388–1402. [Google Scholar] [CrossRef]
  59. de Oliveira, M.F.; Nagao-Dias, A.T.; de Oliveira Pontes, V.M.; Souza Júnior, A.S.; Luna Coelho, H.L.; Branco Coelho, I.C. Etiological treatment of Chagas disease in Brazil. Rev. De Patol. Trop. 2008, 37, 209–228. [Google Scholar] [CrossRef]
  60. Dias, J.C.P.; Coura, J.R. Chagas Disease Clinic and Therapy: A Practical Approach for the General Practitioner; Editora FIOCRUZ: Rio de Janeiro, Brazil, 1997. [Google Scholar] [CrossRef]
  61. Guedes, P.M.M.; Veloso, V.M.; Afonso, L.C.C.; Caliari, M.V.; Carneiro, C.M.; Diniz, L.F.; Marques-da-Silva, E.A.; Caldas, I.S.; do Valle Matta, M.A.; Souza, S.M.; et al. Development of chronic cardiomyopathy in canine Chagas disease correlates with high IFN-γ, TNF-α, and low IL-10 production during the acute infection phase. Vet. Immunol. Immunopathol. 2009, 130, 43–52. [Google Scholar] [CrossRef]
  62. Carlos Pinto Dias, J.; del Grande Cláudio, L.; Maia Lima, M.; Albajar-Viñas, P.; Albuquerque e Silva, R.; Vieira Alves, R.; Maia da Costa, V. Changes in the paradigm of clinical and therapeutic management of Chagas disease: Advances and perspectives in the search for comprehensive health. Epidemiol. E Serviços De Saúde 2016, 25, 1–10. [Google Scholar] [CrossRef]
  63. Esteso, M.A.; Romero, C.M. Cyclodextrins: Properties and Applications. Int. J. Mol. Sci. 2024, 25, 4547. [Google Scholar] [CrossRef] [PubMed]
  64. Rincón-López, J.; Almanza-Arjona, Y.C.; Riascos, A.P.; Rojas-Aguirre, Y. Technological evolution of cyclodextrins in the pharmaceutical field. J. Drug Deliv. Sci. Technol. 2021, 61, 102156. [Google Scholar] [CrossRef] [PubMed]
  65. Aiassa, V.; Garnero, C.; Zoppi, A.; Longhi, M.R. Cyclodextrins and Their Derivatives as Drug Stability Modifiers. Pharmaceuticals 2023, 16, 1074. [Google Scholar] [CrossRef]
  66. Venturini, C.d.G.; Nicolini, J.; Machado, C.; Machado, V.G. Properties and recent applications of cyclodextrins. Química Nova 2008, 31, 360–368. [Google Scholar] [CrossRef]
  67. Davies, C.; Cardozo, R.M.; Negrette, O.S.; Mora, M.C.; Chung, M.C.; Basombrío, M.A. Hydroxymethylnitrofurazone Is Active in a Murine Model of Chagas’ Disease. Antimicrob. Agents Chemother. 2010, 5, 3584–3589. [Google Scholar] [CrossRef]
  68. Ferreira, S.B.; Gonzaga, D.T.G.; Santos, W.C.; de Araújo, K.G.L.; Ferreira, V.F. ß-Lapachone: Medicinal chemistry significance and structural modifications. Rev. Virtual De Química 2010, 2, 140–160. [Google Scholar] [CrossRef]
  69. Dos Anjos, D.O.; Sobral Alves, E.S.; Gonçalves, V.T.; Fontes, S.S.; Nogueira, M.L.; Suarez-Fontes, A.M.; Neves da Costa, J.B.; Rios-Santos, F.; Vannier-Santos, M.A. Effects of a novel β-lapachone derivative on Trypanosoma cruzi: Parasite death involving apoptosis, autophagy, and necrosis. Int. J. Parasitol. Drugs Drug Resist. 2016, 6, 207–219. [Google Scholar] [CrossRef]
  70. Fraceto, L.F.; Gonçalves, M.M.; Moraes, C.M.; Araújo, D.R.; Zanella, L.; Paula, E.; Pertinhez, T.A. Characterization of the ropivacaine:beta-cyclodextrin inclusion complex. Química Nova 2007, 30, 1203–1207. [Google Scholar] [CrossRef]
  71. Kerdpol, K.; Kicuntod, J.; Wolschann, P.; Mori, S.; Rungnim, C.; Kunaseth, M.; Okumura, H.; Kungwan, N.; Rungrotmongkol, T. Cavity Closure of 2-Hydroxypropyl-β-Cyclodextrin: Replica Exchange Molecular Dynamics Simulations. Polymers 2019, 11, 145. [Google Scholar] [CrossRef]
  72. Ignaczak, A.; Orszański, Ł.; Adamiak, M.; Olejniczak, A. B Comparative DFT study of inclusion complexes of thymidine-carborane conjugate with β-cyclodextrin and heptakis(2,6-O-dimethyl)-β-cyclodextrin in water. J. Mol. Liq. 2020, 315, 113767. [Google Scholar] [CrossRef]
  73. Hancu, G.; Papp, L.A.; Tóth, G.; Kelemen, H. The Use of Dual Cyclodextrin Chiral Selector Systems in the Enantioseparation of Pharmaceuticals by Capillary Electrophoresis: An Overview. Molecules 2021, 26, 2261. [Google Scholar] [CrossRef] [PubMed]
  74. Monteiro, L.M.; Tavares, G.D.; Ferreira, E.I.; Consiglieri, V.O.; Bou-Chacra, N.A.; Löbenberg, R. Reverse phase high-performance liquid chromatography for quantification of hydroxymethylnitrofurazone in polymeric nanoparticles. Brazilian J. Pharm. Sci. 2015, 51, 561–567. [Google Scholar] [CrossRef]
  75. Sharma, P.; Singh, M. An ongoing journey of chalcone analogues as single and multi-target ligands in the field of Alzheimer’s disease: A review with structural aspects. Life Sci. 2023, 320, 121568. [Google Scholar] [CrossRef] [PubMed]
  76. Cruz, J.N.; Silva, L.B.; Sousa Filho, J.S.; Vale, J.K.L. Development of New Inhibitors of the Enzyme Dihydroorotate Dehydrogenase (DHODH) from Leishmania sp. Res. Soc. Dev. 2021, 10, e18101623087. [Google Scholar] [CrossRef]
  77. Gonçalves-Santos, E.; Caldas, I.S.; Fernandes, V.Â.; Franco, L.L.; Pelozo, M.F.; Feltrim, F.; Maciel, J.S.; Machado, J.V.C.; Gonçalves, R.V.; Novaes, R.D. Pharmacological potential of new metronidazole/eugenol/dihydroeugenol hybrids against Trypanosoma cruzi in vitro and in vivo. Int. Immunopharmacol. 2023, 121, 110416. [Google Scholar] [CrossRef]
  78. Gomes, C.L.; de Albuquerque Wanderley Sales, V.; Gomes de Melo, C.; Ferreira da Silva, R.M.; Vicente Nishimura, R.H.; Rolim, L.A.; Rolim Neto, P.J. Beta-lapachone: Natural occurrence, physicochemical properties, biological activities, toxicity and synthesis. Phytochemistry 2021, 186, 112713. [Google Scholar] [CrossRef]
  79. Foulkes, M.J.; Tolliday, F.H.; Henry, K.M.; Renshaw, S.A.; Jones, S. Evaluation of the anti-inflammatory effects of synthesised tanshinone I and isotanshinone I analogues in zebrafish. PLoS ONE 2020, 15, e0240231. [Google Scholar] [CrossRef]
  80. Freitas, C.A.B.; Araújo, R.C.S.; Paz, S.P.A.; Silva, J.R.A.; Alves, C.N.; Lameira, J. Obtaining and Characterizing B-Cyclodextrin and Eugenol Inclusion Complex/Preparation and Characterization of Eugenol B-Cyclodextrin Inclusion Complex. Braz. J. Dev. 2021, 7, 33056–33070. [Google Scholar] [CrossRef]
  81. Nagoor Meeran, M.F.; Javed, H.; al Taee, H.; Azimullah, S.; Ojha, S.K. Pharmacological Properties and Molecular Mechanisms of Thymol: Prospects for Its Therapeutic Potential and Pharmaceutical Development. Front. Pharmacol. 2017, 8, 380. [Google Scholar] [CrossRef]
  82. Zhang, Y.; Tan, Y.; OuYang, Q.; Duan, B.; Wang, Z.; Meng, K.; Tan, X.; Tao, N. γ-Cyclodextrin encapsulated thymol for citrus preservation and its possible mechanism against Penicillium digitatum. Pestic. Biochem. Physiol. 2023, 194, 105501. [Google Scholar] [CrossRef] [PubMed]
  83. Serna-Escolano, V.; Serrano, M.; Valero, D.; Isabel Rodríguez-López, M.; Gabaldón, J.A.; Castillo, S.; Valverde, J.M.; Zapata, P.J.; Guillén, F.; Martínez-Romero, D. Thymol Encapsulated into HP-β-Cyclodextrin as an Alternative to Synthetic Fungicides to Induce Lemon Resistance against Sour Rot Decay. Molecules 2020, 25, 4348. [Google Scholar] [CrossRef]
  84. Franco, C.F.J.; Jordão, A.K.; Ferreira, V.F.; Pinto, A.C.; Souza, M.C.B.V.; Resende, J.A.L.C.; Cunha, A.C. Synthesis of new 2-aminocarbohydrate-1,4-naphthoquinone derivatives promoted by ultrasonic irradiation. J. Braz. Chem. Soc. 2011, 22, 187–193. [Google Scholar] [CrossRef]
  85. Dantas, E.; de Souza, F.; Nogueira, W.; Silva, C.; de Azevedo, P.; Soares Aragão, C.; Almeida, P.; Cardoso, M.; da Silva, F.; de Azevedo, E.; et al. Characterization and Trypanocidal Activity of a Novel Pyranaphthoquinone. Molecules 2017, 22, 1631. [Google Scholar] [CrossRef] [PubMed]
  86. da Oliveira, V.S.; Silva, C.C.; de Freitas Oliveira, J.W.; da Silva, M.S.; Ferreira, P.G.; da Siva, F.C.; Ferreira, V.F.; Barbosa, E.G.; Barbosa, C.G.; Moraes, C.B.; et al. The evaluation of in vitro antichagasic and anti-SARS-CoV-2 potential of inclusion complexes of β- and methyl-β-cyclodextrin with naphthoquinone. J. Drug Deliv. Sci. Technol. 2023, 81, 104229. [Google Scholar] [CrossRef]
  87. Chen, Q.; McGillivray, D.; Wen, J.; Zhong, F.; Quek, S.Y. Co-encapsulation of fish oil with phytosterol esters and limonene by milk proteins. J. Food Eng. 2013, 117, 505–512. [Google Scholar] [CrossRef]
  88. Răileanu, M.; Todan, L.; Voicescu, M.; Ciuculescu, C.; Maganu, M. A way for improving the stability of the essential oils in an environmental friendly formulation. Mater. Sci. Eng. C 2013, 33, 3281–3288. [Google Scholar] [CrossRef] [PubMed]
  89. Moghimi, R.; Ghaderi, L.; Rafati, H.; Aliahmadi, A.; McClements, D.J. Superior antibacterial activity of nanoemulsion of Thymus daenensis essential oil against E. coli. Food Chem. 2016, 194, 410–415. [Google Scholar] [CrossRef]
  90. Tobouti, P.L.; de Andrade Martins, T.C.; Pereira, T.J.; Mussi, M.C.M. Antimicrobial activity of copaiba oil: A review and a call for further research. Biomed. Pharmacother. 2017, 94, 93–99. [Google Scholar] [CrossRef]
  91. Ziech, R.E.; Farias, L.D.; Balzan, C.; Ziech, M.F.; Heinzmann, B.M.; Lameira, O.A.; Vargas, A.C. Antimicrobial activity of copaiba oleoresin (Copaifera reticulata) against coagulase-positive Staphylococcus isolated from cases of otitis in dogs. Pesqui. Veterinária Bras. 2013, 33, 909–913. [Google Scholar] [CrossRef]
  92. Menezes, A.C.S.; Alves, L.D.B.; Goldemberg, D.C.; de Melo, A.C.; Antunes, H.S. Anti-inflammatory and wound healing effect of Copaiba oleoresin on the oral cavity: A systematic review. Heliyon 2022, 8, e08993. [Google Scholar] [CrossRef]
  93. Carvalho, J.C.T.; Cascon, V.; Possebon, L.S.; Morimoto, M.S.S.; Cardoso, L.G.V.; Kaplan, M.A.C.; Gilbert, B. Topical antiinflammatory and analgesic activities of Copaifera duckei dwyer. Phytother. Res. 2005, 19, 946–950. [Google Scholar] [CrossRef]
  94. Lima, S.R.M.; Junior, V.F.V.; Christo, H.B.; Pinto, A.C.; Fernandes, P.D. In vivo and in vitro studies on the anticancer activity of Copaifera multijuga hayne and its fractions. Phytother. Res. 2003, 17, 1048–1053. [Google Scholar] [CrossRef] [PubMed]
  95. Pinheiro, J.; Tavares, E.; Silva, S.; Félix Silva, J.; Carvalho, Y.; Ferreira, M.; Araújo, A.; Barbosa, E.; Fernandes Pedrosa, M.; Soares, L.; et al. Inclusion Complexes of Copaiba (Copaifera multijuga Hayne) Oleoresin and Cyclodextrins: Physicochemical Characterization and Anti-Inflammatory Activity. Int. J. Mol. Sci. 2017, 18, 2388. [Google Scholar] [CrossRef]
  96. Kian, D.; Lancheros, C.A.C.; Assolini, J.P.; Arakawa, N.S.; Veiga-Júnior, V.F.; Nakamura, C.V.; Pinge-Filho, P.; Conchon-Costa, I.; Pavanelli, W.R.; Yamada-Ogatta, S.F.; et al. Trypanocidal activity of copaiba oil and kaurenoic acid does not depend on macrophage killing machinery. Biomed. Pharmacother. 2018, 103, 1294–1301. [Google Scholar] [CrossRef] [PubMed]
  97. Lou, J.; Teng, Z.; Zhang, L.; Yang, J.; Ma, L.; Wang, F.; Tian, X.; An, R.; Yang, M.; Zhang, Q.; et al. β-Caryophyllene/Hydroxypropyl-β-Cyclodextrin Inclusion Complex Improves Cognitive Deficits in Rats with Vascular Dementia through the Cannabinoid Receptor Type 2 -Mediated Pathway. Front. Pharmacol. 2017, 8, 2. [Google Scholar] [CrossRef]
  98. Kurkov, S.V.; Loftsson, T. Cyclodextrins. Int. J. Pharm. 2013, 453, 167–180. [Google Scholar] [CrossRef] [PubMed]
  99. Yao, Y.; Xie, Y.; Hong, C.; Li, G.; Shen, H.; Ji, G. Development of a myricetin/hydroxypropyl-β-cyclodextrin inclusion complex: Preparation, characterization, and evaluation. Carbohydr. Polym. 2014, 110, 329–337. [Google Scholar] [CrossRef]
  100. Silva, F.L.O.; Marques, M.B.F.; Yoshida, M.I.; Mussel, W.N.; Silveira, J.V.W.; Barroso, P.R.; Kato, K.C.; Martins, H.R.; Carneiro, G. Encapsulation of benznidazole in nanostructured lipid carriers and increased trypanocidal activity in a resistant Trypanosoma cruzi strain. Braz. J. Pharm. Sci. 2023, 59, e22111. [Google Scholar] [CrossRef]
  101. Gomes, D.C.; Medeiros, T.S.; Alves Pereira, E.L.; da Silva, J.F.O.; de Freitas Oliveira, J.W.; Fernandes-Pedrosa, M.F.; de Sousa da Silva, M.; da Silva-Júnior, A.A. From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease. Int. J. Mol. Sci. 2023, 24, 13778. [Google Scholar] [CrossRef]
  102. Morilla, M.J.; Ghosal, K.; Romero, E.L. Nanomedicines against Chagas disease: A critical review. Beilstein J. Nanotechnol. 2024, 15, 333–349. [Google Scholar] [CrossRef] [PubMed]
  103. Gonzaga, B.M.S.; Nisimura, L.M.; Coelho, L.L.; Ferreira, R.R.; Horita, S.I.M.; Beghini, D.G.; Estato, V.; Araújo-Jorge, T.C.; Garzoni, L.R. Unveiling Lovastatin’s Anti-Inflammatory Potential in Mouse’s Brain during Acute Trypanosoma cruzi Infection. Biology 2024, 13, 301. [Google Scholar] [CrossRef] [PubMed]
  104. Narwal, S.; Dhanda, T.; Sharma, P.; Sharma, V.; Dhankhar, S.; Garg, N.; Ghosh, N.S.; Rani, N. Current Therapeutic Strategies for Chagas Disease. Anti-Infect. Agents 2024, 22, 20–30. [Google Scholar] [CrossRef]
  105. García-Huertas, P.; Cardona-Castro, N. Advances in the treatment of Chagas disease: Promising new drugs, plants and targets. Biomed. Pharmacother. 2021, 142, 112020. [Google Scholar] [CrossRef]
Ijms 25 09511 g001
Figure 1. Flowchart illustrating the methodology employed for article selection.
Figure 1. Flowchart illustrating the methodology employed for article selection.
Ijms 25 09511 g001
Ijms 25 09511 g002
Figure 2. The format of natural cyclodextrins according to the amount of the glycosidic group.
Figure 2. The format of natural cyclodextrins according to the amount of the glycosidic group.
Ijms 25 09511 g002
Ijms 25 09511 g003
Figure 3. The external and internal cavities of cyclodextrins.
Figure 3. The external and internal cavities of cyclodextrins.
Ijms 25 09511 g003
Ijms 25 09511 g004
Figure 4. Schematic representation of the formation of an inclusion complex with cyclodextrins.
Figure 4. Schematic representation of the formation of an inclusion complex with cyclodextrins.
Ijms 25 09511 g004
Ijms 25 09511 g005
Figure 5. The biological cycle of Chagas disease in the human host.
Figure 5. The biological cycle of Chagas disease in the human host.
Ijms 25 09511 g005
Ijms 25 09511 g006
Figure 6. Benznidazole (on the left) and Nifurtimox (on the right) drugs for the treatment of Chagas disease.
Figure 6. Benznidazole (on the left) and Nifurtimox (on the right) drugs for the treatment of Chagas disease.
Ijms 25 09511 g006
Ijms 25 09511 g007
Figure 7. Evolution of the number of scientific publications on Chagas disease in the last 5 years.
Figure 7. Evolution of the number of scientific publications on Chagas disease in the last 5 years.
Ijms 25 09511 g007
Table 2. Physicochemical properties of natural cyclodextrins [25].
Table 2. Physicochemical properties of natural cyclodextrins [25].
CyclodextrinGlucose Unit NumberMolecular WeightCavity Diameter (Å)Cavity Volume (Å3)Aqueous Solubility at 25° C
(% m/v)
α-CD69724.5–5.317414.5
β-CD711356.0–6.52621.85
γ-CD812977.5–8.342723.2
Table 3. Side effects observed in the specific treatment of Chagas disease [60].
Table 3. Side effects observed in the specific treatment of Chagas disease [60].
Symptom/SignBenznidazolNifurtimox
Anorexia+++++
Headache+++
Dermatopathy++++
Psychic excitement-+++
Gastralgia++++
Insomnia+++
Nausea+++++
Weight loss++++
Polyneuropathy++++
Vomiting+++++
Legend: - (no effect), + (almost no effect), ++ (moderate effect), +++ (pronounced effect).
Table 4. Structures of the cyclodextrins most used to treat Chagas disease.
Table 4. Structures of the cyclodextrins most used to treat Chagas disease.
Type of CyclodextrinReferenceCyclodextrin Structure
β-cyclodextrin
(β-CD)		[70]Ijms 25 09511 i001
2-Hydroxypropyl-β-cyclodextrin
(HP-β-CD)		[71]Ijms 25 09511 i002
Dimethyl-β-cyclodextrin
(DM-β-CD)		[72]Ijms 25 09511 i003
Ether sulfobutílico-β-cyclodextrin
(SBE-β-CD)		[73]Ijms 25 09511 i004
Table 5. Structures of the drugs tested to carry out the inclusion complex against T. cruzi.
Table 5. Structures of the drugs tested to carry out the inclusion complex against T. cruzi.
Molecule NameReferenceMolecular Structure
HidroximetilNitrofurazone
(NFOH)		[74]Ijms 25 09511 i005
Chalcones
(CHC)		[75]Ijms 25 09511 i006
O-allyl-lawsone
(OAL)		[12]Ijms 25 09511 i007
Nifurtimox
(NF)		[76]Ijms 25 09511 i008
Benznidazole
(BNZ)		[76]Ijms 25 09511 i009
Metronidazole
(MTZ)		[77]Ijms 25 09511 i010
β-lapachone
(β-Lap)		[78]Ijms 25 09511 i011
Nor-β-lapachone
(NβL)		[79]Ijms 25 09511 i012
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Taio, F.; Converti, A.; Lima, Á.A.N.d. Cyclodextrin Complexes for the Treatment of Chagas Disease: A Literature Review. Int. J. Mol. Sci. 2024, 25, 9511. https://doi.org/10.3390/ijms25179511

AMA Style

Taio F, Converti A, Lima ÁANd. Cyclodextrin Complexes for the Treatment of Chagas Disease: A Literature Review. International Journal of Molecular Sciences. 2024; 25(17):9511. https://doi.org/10.3390/ijms25179511

Chicago/Turabian Style

Taio, Fabrice, Attilio Converti, and Ádley Antonini Neves de Lima. 2024. "Cyclodextrin Complexes for the Treatment of Chagas Disease: A Literature Review" International Journal of Molecular Sciences 25, no. 17: 9511. https://doi.org/10.3390/ijms25179511

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop